Oppenheimer is out with its report today on Incyte INCY, raising its PT from $25 to $23.
In a note to clients, Oppenheimer writes, "We conducted a survey of 25 practicing oncologists regarding INCB18424's potential in myelofibrosis and polycythemia vera. The survey results support our view that '424 will become a dominant MF/PV therapy, based on the drug's favorable clinical profile and the significant unmet need in these indications. Importantly, our survey suggests '424's adoption in MF and, notably, off-label use in PV, will likely be meaningfully higher than we had previously anticipated. As a result, we have increased our '424 sales estimates. We believe INCY's current valuation does not fully reflect '424's potential in MF/PV and believe full ph.III MF results at ASCO should be an important near-term catalyst for the stock. Raising PT to $25, from $23, on revised estimates."
Shares of INCY closed Wednesday at $19.31, down 0.05% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in